玻璃体腔注射抗血管内皮生长因子药物治疗早产儿视网膜病变联合护理研究

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (665 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of combined nursing intervention in retinopathy of prematurity(ROP) treated with intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Methods A total of 60 infants with ROP admitted to Department of Ophthalmology, the First Hospital of Nanchang from January 2019 to December 2021 were selected as the research objects. They were divided into the observation group and the control group by random number table method, with 30 cases in each group. Both groups were treated with intravitreal injection of anti-VEGF drugs.The observation group received ward combined with operating room optimized nursing,and the control group received routine nursing intervention. The two groups were compared in terms of clinical effect, and the total incidence rates of adverse events such as dyspnea, asphyxia, gas accumulation in vitreous cavity, infection, retinal detachment and endophthalmitis. Results The total treatment response rate showed no statistically significant difference between the two groups (P＞0.05). The total incidence of adverse events in the observation group was lower than in the control group, with statistically significant difference (P＜0.05). Conclusion Combined nursing intervention for infants with ROP treated with intravitreal injection of anti-VEGF drugs can effectively reduce postoperative adverse events and improve the prognosis.

Key words： Intravitreal injection of anti-vascular endothelial growth factor Premature infant Retinopathy Combined nursing

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Yueyuan
	LI Yingjie
	ZHU Xuan
	YOU Xiaohua

Cite this article:

XU Yueyuan,LI Yingjie,ZHU Xuan, et al. Study on the combined nursing for retinopathy of prematurity treated with intravitreal injection of anti -vascular endothelial growth factor drugs[J]. 中国当代医药, 2022, 29(24): 170-172.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I24/170

[1]	Quinn GE，Barr C，Bremer D，et al.Changes in Course of Retinopathy of Prematurity from 1986 to 2013 Comparison of Three Studies in the United States[J].Ophthalmology，2016，123（7）：1595-1600.
[2]	李曼红，王亮，张自峰，等.两种抗VEGF 药物治疗1 型早产儿视网膜病变的疗效比较[J].国际眼科杂志，2021，21（5）：866-871.
[3]	Stahl A，Lepore D，Fielder A，et al.Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW)：An open-label randomised controlled trial[J].Lancet，2019，394（10208）：1551-1559.
[4]	许晓璇，吴雅俊，吴红云，等.早产儿视网膜病变研究新进展[J].中国医学科学院学报，2019，41（2）：261-266.
[5]	赵欢欢，李静，穆歌，等.玻璃体腔注射雷珠单抗治疗早产儿视网膜病变的临床疗效[J].中国斜视与小儿眼科杂志，2018，26（3）：20-23.
[6]	中华医学会眼科学分会眼底病学组.中国早产儿视网膜病变筛查指南（2014年）[J].中华眼科杂志，2014，50（12）：933-935.
[7]	Vanderveen DK，Melia M，Yang MB，et al.Anti -Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity：A Report by the American Academy of Ophthalmology[J].Ophthalmology，2017，124（5）：619-633.
[8]	顾起宏.早产儿视网膜病变的研究进展[J].实用防盲技术，2015（1）：39-44.
[9]	刘梅.玻璃体腔注射雷珠单抗治疗早产儿视网膜病变疗效分析[J].中国实用眼科杂志，2017，35（7）：718-721.
[10]	王宗华，李秋平，杨秀梅，等.康柏西普和雷珠单抗治疗早产儿视网膜病变的疗效分析[J].中华眼视光学与视觉科学杂志，2021，23（11）：858-863.
[11]	吴丹，陈亚香，梁燕,等.玻璃体腔注药治疗早产儿视网膜病变的护理配合及围术期安全管理[J].齐鲁护理杂志，2022，28（2）：141-143.
[12]	周玲玲，汪磊.早产儿视网膜病变患儿照顾者照护体验的质性研究[J].中国实用护理杂志，2016，32（25）：1963-1965.
[13]	樊静，周毅，苟凯丽，等.早产儿视网膜病变玻璃体腔注药术围手术期规范化护理[J].西南国防医药，2021，31（4）：333-335.
[14]	陈庆玲，韦文永，符婵，等.早产儿视网膜病变围手术期护理体会[J].当代护士（上旬刊），2018，25（2）：106-108.
[15]	张明琴.早产儿视网膜病变玻璃体腔注射雷珠单抗的护理[J].中国卫生标准管理，2021，12（8）：153-156.